Metacrine Inc.

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Investing News NetworkYour trusted source for investing success

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Rare Earths Stocks: 9 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Mark These Tax-loss Selling Dates on Your Calendar (Updated 2024)

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

Purpose Bitcoin ETF

First Helium

Soma Gold Corp.

GTI Energy

2024 Gold Outlook Report

2024 Uranium Outlook

Silver Price Forecast - What Happened And Where Do We Go From Here?

Rare Earths Outlook Report

Metacrine Inc.

5 US Longevity and Anti-aging Stocks to Watch in 2024

Stem Cell Stocks: 10 Biggest NASDAQ Companies

Interactive Chart